Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics

Overview

Journal Front Pharmacol

Date 2018 Mar 17

PMID 29545753

Citations 12

Authors

Emmanuelle A D Schindler

Ryan M Wallace

Jordan A Sloshower

Deepak C DSouza

Affiliations

Soon will be listed here.

Abstract

Recent reports on the effects of psychedelic-assisted therapies for mood disorders and addiction, as well as the effects of psychedelics in the treatment of cluster headache, have demonstrated promising therapeutic results. In addition, the beneficial effects appear to persist well after limited exposure to the drugs, making them particularly appealing as treatments for chronic neuropsychiatric and headache disorders. Understanding the basis of the long-lasting effects, however, will be critical for the continued use and development of this drug class. Several mechanisms, including biological and psychological ones, have been suggested to explain the long-lasting effects of psychedelics. Actions on the neuroendocrine system are some such mechanisms that warrant further investigation in the study of persisting psychedelic effects. In this report, we review certain structural and functional neuroendocrinological pathologies associated with neuropsychiatric disorders and cluster headache. We then review the effects that psychedelic drugs have on those systems and provide preliminary support for potential long-term effects. The circadian biology of cluster headache is of particular relevance in this area. We also discuss methodologic considerations for future investigations of neuroendocrine system involvement in the therapeutic benefits of psychedelic drugs.

Citing Articles

A transcriptomic analysis in mice following a single dose of ibogaine identifies new potential therapeutic targets.

Biosca-Brull J, Ona G, Alarcon-Franco L, Colomina M Transl Psychiatry. 2024; 14(1):41.

PMID: 38242896 PMC: 10798990. DOI: 10.1038/s41398-024-02773-7.

Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats.

Reinwald J, Schmitz C, Skorodumov I, Kuchar M, Weber-Fahr W, Spanagel R Transl Psychiatry. 2023; 13(1):392.

PMID: 38097569 PMC: 10721862. DOI: 10.1038/s41398-023-02690-1.

Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice.

Jones N, Zahid Z, Grady S, Sultan Z, Zheng Z, Razidlo J ACS Pharmacol Transl Sci. 2023; 6(8):1221-1231.

PMID: 37588757 PMC: 10425994. DOI: 10.1021/acsptsci.3c00123.

Transcriptomic Analysis of Glycosylation and Neuroregulatory Pathways in Rodent Models in Response to Psychedelic Molecules.

Oommen A, Roberts K, Joshi L, Cunningham S Int J Mol Sci. 2023; 24(2).

PMID: 36674723 PMC: 9867456. DOI: 10.3390/ijms24021200.

Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis.

Kelly J, Clarke G, Harkin A, Corr S, Galvin S, Pradeep V Int J Clin Health Psychol. 2023; 23(2):100349.

PMID: 36605409 PMC: 9791138. DOI: 10.1016/j.ijchp.2022.100349.

References

Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert H, Kovar K, Lindenblatt H . Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl). 1999; 142(1):41-50. DOI: 10.1007/s002130050860. View

Uvnas-Moberg K, Bjokstrand E, Hillegaart V, Ahlenius S . Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacology (Berl). 1999; 142(1):95-101. DOI: 10.1007/s002130050867. View

Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M . Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999; 20(6):565-81. DOI: 10.1016/S0893-133X(98)00089-X. View

May A, Ashburner J, Buchel C, McGonigle D, Friston K, Frackowiak R . Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat Med. 1999; 5(7):836-8. DOI: 10.1038/10561. View

Mukherjee J, Yang Z, Brown T, Lew R, Wernick M, Ouyang X . Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol. 1999; 26(5):519-27. DOI: 10.1016/s0969-8051(99)00012-8. View

Mackowiak M, Chocyk A, Fijal K, Czyrak A, Wedzony K . c-Fos proteins, induced by the serotonin receptor agonist DOI, are not expressed in 5-HT2A positive cortical neurons. Brain Res Mol Brain Res. 1999; 71(2):358-63. DOI: 10.1016/s0169-328x(99)00195-3. View

Kennaway D, Moyer R . MK-801 administration blocks the effects of a 5-HT(2A/2C) agonist on melatonin rhythmicity and c-fos induction in the suprachiasmatic nucleus. Brain Res. 1999; 845(1):102-6. DOI: 10.1016/s0006-8993(99)01951-4. View

Okubo Y, Olsson H, Ito H, Lofti M, Suhara T, Halldin C . PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [11C]FLB 457. Neuroimage. 1999; 10(6):666-74. DOI: 10.1006/nimg.1999.0502. View

Winter J, Filipink R, Timineri D, Helsley S, Rabin R . The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol Biochem Behav. 2000; 65(1):75-82. DOI: 10.1016/s0091-3057(99)00178-1. View

10.

Marazziti D, Rossi A, Giannaccini G, Zavaglia K, DellOsso L, Lucacchini A . Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur Neuropsychopharmacol. 2000; 10(1):21-6. DOI: 10.1016/s0924-977x(99)00045-0. View

11.

Neumann I, Torner L, Wigger A . Brain oxytocin: differential inhibition of neuroendocrine stress responses and anxiety-related behaviour in virgin, pregnant and lactating rats. Neuroscience. 2000; 95(2):567-75. DOI: 10.1016/s0306-4522(99)00433-9. View

12.

Raghavendra V, Kulkarni S . Melatonin reversal of DOI-induced hypophagia in rats; possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of HPA axis. Brain Res. 2000; 860(1-2):112-8. DOI: 10.1016/s0006-8993(00)02031-x. View

13.

Leone M, DAmico D, Frediani F, Moschiano F, Grazzi L, Attanasio A . Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology. 2000; 54(6):1382-5. DOI: 10.1212/wnl.54.6.1382. View

14.

Steardo L, Monteleone P, Trabace L, Cannizzaro C, Maj M, Cuomo V . Serotonergic modulation of rat pineal gland activity: in vivo evidence for a 5-Hydroxytryptamine(2C) receptor involvement. J Pharmacol Exp Ther. 2000; 295(1):266-73. View

15.

Aloyo V, Harvey J . Antagonist binding at 5-HT(2A) and 5-HT(2C) receptors in the rabbit: high correlation with the profile for the human receptors. Eur J Pharmacol. 2000; 406(2):163-9. DOI: 10.1016/s0014-2999(00)00645-2. View

16.

Biswas B, Ghosh J . Delta-9-tetrahydrocannabinol and lysergic acid diethylamide: comparative changes in the supraoptic and paraventricular neurosecretory activities in rat hypothalamus. Anat Anz. 1975; 138(4):324-31. View

17.

May A, Goadsby P . Hypothalamic involvement and activation in cluster headache. Curr Pain Headache Rep. 2001; 5(1):60-6. DOI: 10.1007/s11916-001-0011-4. View

18.

Kennaway D, Moyer R, Voultsios A, Varcoe T . Serotonin, excitatory amino acids and the photic control of melatonin rhythms and SCN c-FOS in the rat. Brain Res. 2001; 897(1-2):36-43. DOI: 10.1016/s0006-8993(01)02091-1. View

19.

Van de Kar L, Javed A, Zhang Y, Serres F, Raap D, Gray T . 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci. 2001; 21(10):3572-9. PMC: 6762485. View

20.

Hemrick-Luecke S, Evans D . Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis. Neuropharmacology. 2002; 42(2):162-9. DOI: 10.1016/s0028-3908(01)00166-6. View